Follow-up of Blood-Pressure Lowering and Glucose Control in Type 2 Diabetes

Study Questions:

Among surviving patients from the ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation) trial, what is the impact of blood pressure–lowering therapy and intensive glucose control on cardiovascular outcomes at 6-year post-trial follow-up?